Skip to content
2000
Volume 20, Issue 3
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

This article reviews preclinical and clinical studies on the repurposed use of disulfiram (Antabuse) as an antimicrobial agent. Preclinical research covered on the alcohol sobriety aid includes uses as an anti-MRSA agent, a carbapenamase inhibitor, antifungal drug for candidiasis, and treatment for parasitic diseases due to protozoa (e.g., giardiasis, leishmaniasis, malaria) and helminthes (e.g., schistosomiasis, trichuriasis). Past, current, and pending clinical studies on disulfiram as a post-Lyme disease syndrome (PTLDS) therapy, an HIV latency reversal agent, and intervention for COVID-19 infections are also reviewed..

Loading

Article metrics loading...

/content/journals/aia/10.2174/2211352520666220104104747
2022-06-01
2025-06-14
Loading full text...

Full text loading...

/content/journals/aia/10.2174/2211352520666220104104747
Loading

  • Article Type:
    Review Article
Keyword(s): antabuse; antimicrobial; COVID; Disulfiram; HIV; lyme disease; MRSA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test